As China Volume Purchase Builds, Novartis Scrambles To Launch New Products
The Largest VBP Looming
China’s latest volume-based purchase round is also the largest ever, covering more drugs and many of them are the widest-prescribed products. Novartis feels the pinch of price pressures but emphasizes a shift to new product launches.
You may also be interested in...
Chi-Med has revised its commercial rights agreement in China for Elunate (fruquintinib) with Lilly to seize China’s rapid growth trajectory, CEO Christian Hogg tells Scrip.
Despite leading multinational pharma firms including AstraZeneca again delivering double-digit growth in China, the impact of coronavirus and an expanding volume-based purchasing scheme begin to surface.
In a bold move to expand into cancer treatment markets, Siemens Healthineers has agreed to a $16.4bn all-cash deal to acquire radiation therapy leader Varian.